Johnson & Johnson has agreed to acquire Ambrx Biopharma for approximately $2 billion. The transaction, announced Jan. 8, is expected to close in the first half of 2024. La Jolla, California-based Ambrx was represented by a Skadden, Arps, Slate, Meagher & Flom team including partners Ray Bogenrief, Maria Raptis, Graham Robinson, Resa Schlossberg, Chade Severin and Moshe Spinowitz. Counsel information for Johnson & Johnson was not immediately available.
Biotech & Pharmaceuticals
January 09, 2024, 10:24 AM